Shares of Amedisys Inc. (NASDAQ:AMED) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $55.09 and last traded at $54.85, with a volume of 136,875 shares changing hands. The stock had previously closed at $53.55.

Several analysts have issued reports on the stock. Mizuho downgraded shares of Amedisys from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $57.00 to $55.00 in a research report on Wednesday. Zacks Investment Research downgraded shares of Amedisys from a “hold” rating to a “sell” rating in a research report on Monday, July 11th. Stephens assumed coverage on shares of Amedisys in a research report on Thursday, June 16th. They issued an “equal weight” rating and a $55.00 price objective for the company. Jefferies Group reaffirmed a “buy” rating and issued a $59.00 price objective on shares of Amedisys in a research report on Wednesday, May 25th. Finally, Robert W. Baird reaffirmed a “hold” rating on shares of Amedisys in a research report on Monday, May 16th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $51.75.

The stock has a market cap of $1.80 billion and a PE ratio of 46.56. The stock has a 50-day moving average of $51.43 and a 200 day moving average of $46.40.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported $0.42 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.42. The company earned $360 million during the quarter, compared to the consensus estimate of $353.07 million. The firm’s revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 earnings per share. On average, equities analysts predict that Amedisys Inc. will post $1.74 EPS for the current fiscal year.

In other Amedisys news, insider Scott G. Ginn sold 6,000 shares of Amedisys stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $51.62, for a total value of $309,720.00. Following the transaction, the insider now directly owns 48,009 shares of the company’s stock, valued at approximately $2,478,224.58. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bruce D. Perkins purchased 1,000 shares of the company’s stock in a transaction on Friday, May 13th. The stock was acquired at an average cost of $50.21 per share, for a total transaction of $50,210.00. Following the completion of the transaction, the director now owns 10,354 shares in the company, valued at $519,874.34. The disclosure for this purchase can be found here.

A number of hedge funds and institutional investors have modified their holdings of the company. Trexquant Investment LP acquired a new position in shares of Amedisys during the fourth quarter valued at approximately $1,031,000. Cornerstone Capital Management Holdings LLC. increased its position in shares of Amedisys by 230.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 31,100 shares of the company’s stock valued at $1,223,000 after buying an additional 21,700 shares in the last quarter. Rhumbline Advisers increased its position in shares of Amedisys by 5.3% in the fourth quarter. Rhumbline Advisers now owns 37,499 shares of the company’s stock valued at $1,474,000 after buying an additional 1,875 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Amedisys by 20.3% in the fourth quarter. GSA Capital Partners LLP now owns 38,192 shares of the company’s stock valued at $1,502,000 after buying an additional 6,437 shares in the last quarter. Finally, Sei Investments Co. increased its position in shares of Amedisys by 1,922,350.0% in the fourth quarter. Sei Investments Co. now owns 38,449 shares of the company’s stock valued at $1,512,000 after buying an additional 38,447 shares in the last quarter.

Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.